期刊文献+

缺失PRD的人FOXP3单克隆抗体的制备与鉴定 被引量:1

原文传递
导出
摘要 目的:制备抗脯氨酸富含区缺失的人FOXP3(△PRD-hFOXP3)的单克隆抗体(mAb),为进一步研究人FOXP3各片段功能奠定基础。方法:以纯化的△PRD-hFOXP3重组蛋白为抗原免疫BALB/c小鼠,取免疫小鼠的脾细胞和骨髓瘤细胞Sp2/0进行常规融合,经筛选及克隆化建立2株分泌抗△PRD-hFOXP3的mAb杂交瘤细胞株;利用核型分析、间接ELISA及Western blot分别鉴定了杂交瘤的细胞核型、抗体的效价与特异性。结果:筛选到2株可稳定分泌抗△PRD-hFOXP3的mAb的细胞株,分别命名为1A2和3A11;2株抗体均为IgG1,腹水经ELISA方法测定效价均可达1∶105;Western blot显示这2株杂交瘤分泌的mAb均可与△PRD-hFOXP3蛋白特异性地结合。结论:成功获得2株能稳定分泌特异性抗△PRD-hFOXP3的mAb的杂交瘤细胞株,可用于人FOXP3的进一步研究及相关试剂的研发等。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2010年第6期566-568,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30671984) 江苏大学科技创新团队资助项目(2008-018-02)
  • 相关文献

参考文献10

  • 1Lopes JE, Torgerson TR, Schubert LA, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor[J]. J Immunol, 2006, 177(5) : 3133 -3142.
  • 2Carlsson P, Mablapuu M. Forkhead transcription factors: key players in development and metabolism[J].Dev Biol, 2002, 250( 1 ) : 1 - 23.
  • 3汪家政,范明.蛋白质技术手册[M].北京:科学出版社,2005:65—67.
  • 4周群芳,鞠吉雨,郎景和.抗人骨桥蛋白单克隆抗体的制备及鉴定[J].细胞与分子免疫学杂志,2009,25(1):62-64. 被引量:5
  • 5明志君,吴海竞,张光波,胡玉敏,邱玉华,张学光.两株鼠抗人PD-1单克隆抗体的制备及其生物学特性鉴定[J].细胞与分子免疫学杂志,2009,25(6):501-503. 被引量:6
  • 6Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective[ J]. Eur J Immunol, 2007, 37 (Suppl 1 ) : S116 - 123.
  • 7Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3[J]. Nat Genet, 2001,27(1) : 20 - 21.
  • 8Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity [ J]. Immunol Res, 2007, 38 (1 - 3): 112-121.
  • 9Lin W, Haribhai D, Relland LM, et al. Regulatory T cell development in the absence of functional Foxp3 [ J ]. Nat Immunol, 2007, 8 (4) : 359 -368.
  • 10Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression [ J ]. Nature, 2007, 445(7129) : 766 -770.

二级参考文献17

  • 1马彩虹,陈贵安,韩劲松,齐永芬.骨桥蛋白在人正常月经周期子宫内膜的表达[J].生殖医学杂志,2006,15(1):1-5. 被引量:7
  • 2Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant( v6, v9 )expression by osteopontin in breast cancer epithelial ceils facilitates tumor cell migration: Novel post transcriptional, post translational regulation [ J ]. Clin Exp Metastasis, 2005, 22 ( 8 ) : 663 - 673.
  • 3Rittling SR, Chambers AF. Role of osteopontin in tumor progression [J]. Br J Cancer, 2004, 90(10) : 1877 - 1551.
  • 4Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer[ J]. JAMA, 2002, 287 ( 13 ) : 1671 - 1679.
  • 5White FJ, Ross JW, Joyce MM, et al. Steroid regulation of cell specitic secreted phosphoprotein 1 (osteopontin)expression in the pregnant porcine uterus[J].Biol Reprod, 2005, 73 (6) : 1294 - 1301.
  • 6Weintraub AS, Lin X, Itskovich VV, et al. Prenatal detection of embryo resorption in osteopontin deficient mice using serial noninvasive magnetic respane microscopy[ J]. Pediatr Res, 2004, 55 (3) : 419 - 424.
  • 7Helluint O, Chan C, Vilaire G, et al. The activation state of αvβ3 regulates platelet and lymphocyte adhesion to intact and thrombin cleaved osteopontin [ J ]. J Biol Chem, 2000, 275 (24) : 18337 - 18343.
  • 8Ishida Y,Agata Y,Shibahara K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
  • 9Nishimura H,Honjo T,Minato N.Facilitation of β-selection and modification of positive selection in the thymus of PD-1 deficient mice[J].J Exp Med,2002,191(5):891-898.
  • 10Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.

共引文献31

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部